Across TCGA pan-cancer cohorts, SLC26A6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC26A6 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC26A6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC26A6 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and LSCC are the cancer types where SLC26A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.230	0.678	.013	16	view →
LUAD	DFS	Quartile	All	0.469	0.739	.027	6	view →
LSCC	DFS	Median	II,III,IV	0.482	0.928	.019	3	view →
HNSC	DFS	Tertile	IV	0.448	0.820	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SLC26A6 tumor-vs-normal RNA expression · all SLC26A6 data types